Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7381519 | 0.98 | LMNA (0.47) | LMNAGAACYP2D6ALDH1A1KMT2A | |
| SCHEMBL13106060 | 0.95 | LMNA (0.49) | LMNAGAAALDH1A1KMT2ATSHR | |
| SCHEMBL15265428 | 0.95 | LMNA (0.49) | LMNAGAAALDH1A1KMT2ATSHR | |
| SCHEMBL5992612 | 0.95 | LMNA (0.49) | LMNAGAAALDH1A1KMT2ATSHR | |
| SCHEMBL80480 | 0.88 | LMNA (0.58) | LMNAGAAALDH1A1KMT2ATSHR | |
| SCHEMBL905284 | 0.88 | LMNA (0.58) | LMNAGAAALDH1A1KMT2ATSHR | |
| SCHEMBL815103 | 0.88 | LMNA (0.58) | LMNAGAAALDH1A1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL29400035 | 0.87 | LMNA (0.57) | LMNAGAACYP2D6ALDH1A1KMT2A | |
| SCHEMBL7387145 | 0.83 | ALDH1A1 (0.42) | LMNACYP2D6ALDH1A1KMT2ATSHR | |
| Pidolic Acid SCHEMBL14859342 | 0.83 | LMNA (0.53) | LMNAGAACYP2D6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2008031788-A1 | AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE | NYCOMED GMBH (DE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031788-A1 | AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE | NYCOMED GMBH (DE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | LMNA 4289/4885GAA 2691/4885CYP2D6 283/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | LMNA 4289/4885GAA 2691/4885CYP2D6 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.